厄贝沙坦对维持性血液透析患者微炎症状态的影响

Effect of irbesartan on microinflammation in patients with maintenance hemodialysis

目的:探讨厄贝沙坦对维持性血液透析(MHD)患者微炎症状态的影响。方法:选择52例行MHD治疗的慢性肾衰患者,随机分为厄贝沙坦治疗组27例和非厄贝沙坦治疗组25例,并设28例健康对照组作为比较,检测治疗前及治疗6个月后血清C-反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)。结果:尿毒症MHD组CRP,IL-6,TNF-α显著高于健康对照组(P<0.01),治疗6个月后,厄贝沙坦治疗组CRP,IL-6,TNF-α的水平均有所下降,厄贝沙坦治疗组CRP,IL-6,TNF-α下降的水平与治疗前及非厄贝沙坦治疗组相比,差异具有显著性(P<0.05);非厄贝沙坦治疗组CRP,IL-6,TNF-α的水平较治疗前有所上升(P<0.05)。结论:尿毒症患者体内存在微炎症状态,厄贝沙坦可改善MHD患者的微炎症状态。

Objective： To investigate the effects of irbesartan on microinflammation state in patients with maintenance hemodialysis. Methods： Urinemia patients with maintenance hemodialysis （n = 52） were randomly divided into 2 groups and treated with irbesartan 150 mg daily or other drugs; 28 healthy subjects were enrolled as control. The serum levels of C-reative protein （CRP）, interlukin-6 （IL-6）, tumor necrosis factor alpha （TNF-α） were determined before and 6 months after the treatments. Results： As compared with healthy control, the serum CRP, IL-6 and TNF- were significantly elevated in patients with maintenance hemodialysis （P 〈 0.01 ）. After treatment with irbesartan for 6 month, the levels of CRP, IL-6 and TNF- were reduced. However, after treatment with other drugs, the levels were increased. There was significant difference in the levels between 2 groups （P 〈 0.05 ）. Conclusion ： Microinflammation state exists in urinemia patients. Irbesartan can relieve the mieroinflammation state in patients with maintenance hemodialysis.